When was Anocca founded?

Anocca was founded in 2014 and raised its 1st funding round 7 years after it was founded.

Where is Anocca located?

Anocca is headquartered in Sodertalje, Sweden.

How many employees does Anocca have?

As of Jul 31, 2026, the latest employee count at Anocca is 123.

Is Anocca a funded company?

Anocca is a funded company, having raised a total of $166M across 4 funding rounds to date. The company's 1st funding round was a $***** Series B round, raised on Jul 22, 2021.

When was the latest funding round of Anocca?

Anocca's latest funding was a $***** Series D round on Aug 19, 2025, with participation from 2 investors.

Where does Anocca rank among its competitors?

Anocca ranks 251st amongst 3346 active competitors, of which 1143 are funded. It stands 7th in terms of total funding among its competitors. The most recent competitor to raise funding was Immuneel, which secured $10.5M in Jun, 2026.

Who are the top competitors of Anocca?

Anocca's top competitors include Jazz Pharmaceuticals, Sana Biotechnology and Ideaya Biosciences. Among them, Immuneel secured the most recent funding round in June, 2026.

Anocca - 2026 Company Profile, Team, Funding & Competitors

Company Details

Developer of personalized immunotherapeutics for oncology, autoimmune and inflammatory diseases. The company has TCR-modified T-cell therapies against multiple antigen classes, tumours, genetic mutations, and viruses that cause cancer. The proprietary Immuno-technology platform for its target discovery, validation, and product development.

Website: www.anocca.com/
Email ID: *****@anocca.com
Phone Number: +46 **********

Key Metrics

Founded Year

2014

Location

Sodertalje, Sweden

Stage

Series D

Total Funding

$166M in 4 rounds

Latest Funding Round

Series D, Aug 19, 2025, $*****

Investors

Mellby Gård & 8 more

Ranked

251^st among 3346 active competitors

Employee Count

123 as on Jul 31, 2026

Similar Companies

Jazz Pharmaceuticals & 3151 more

View Anocca's full profile

Anocca has raised a total funding of $166M over 4 rounds. Its first funding round was on Jul 22, 2021. Its latest funding round was a Series D round on Aug 19, 2025 for $*****. 2 investors participated in its latest round. Anocca has 9 institutional investors.

Here is the list of recent funding rounds of Anocca:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Aug 19, 2025	4037500	Series D	4118093	9706507	6091006	7667553
May 31, 2023	7144001	Series C	2413004	4097104	1250982	Michano & 2 more
Dec 21, 2022	1237473	Venture Debt	9494449	2249165	4614492	European Investment Bank

Access funding benchmarks and valuations. Sign up today!

View details of Anocca's funding rounds and investors

The founders of Anocca is Reagan Jarvis.

Here are the details of Anocca's key team members:

Reagan Jarvis: Co-Founder & CEO of Anocca.
Contact Info: 1 email address

View details of Anocca's Founder profiles and Board Members

Anocca's employee count trend

Anocca has 123 employees as of Jul 26. Here is Anocca's employee count trend over the years:

Uncover Anocca's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Anocca include Jazz Pharmaceuticals, Sana Biotechnology and Ideaya Biosciences. Here is the list of Top 10 competitors of Anocca, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	82/100
2nd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, Google Ventures & 17 others	74/100
3rd	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	73/100
4th	Senti Bio 2016, San Francisco (United States), Public	Developer of cell and gene therapies for patients living with incurable diseases	$158M	Celadon Partners, New Enterprise Associates ... & 30 others	72/100
5th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
6th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
7th	Karyopharm 2008, Newton (United States), Public	Biopharmaceutical company focused on developing and commercializing innovative cancer therapies	$98.4M	Foresite Capital, Avidity Partners & 16 others	72/100
8th	Moderna 2010, Cambridge (United States), Public	Developer of mRNA-based therapeutics for a wide range of diseases	$2.78B	Merck, AstraZeneca & 32 others	71/100
9th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	True North, F-Prime Capital & 23 others	71/100
10th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
251st	Anocca 2014, Sodertalje (Sweden), Series D	Deevloper of personalized immunotherapeutics for oncology, autoimmune and inflammatory diseases	$166M	Danske Bank, European Investment Bank & 7 others	58/100